Patrick Aubonnet
Overview
Explore the profile of Patrick Aubonnet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun B, Sengupta N, Rao A, Donnelly C, Waichale V, Roy A, et al.
BMC Endocr Disord
. 2021 Jun;
21(1):129.
PMID: 34174848
Background: MYL-1501D is a proposed biosimilar to insulin glargine. The noninferiority of MYL-1501D was demonstrated in patients with type 1 diabetes and type 2 diabetes in 2 phase 3 trials....
2.
Heise T, Donnelly C, Barve A, Aubonnet P
Diabetes Obes Metab
. 2019 Nov;
22(4):521-529.
PMID: 31724253
Aims: To report phase 1 bioequivalence results comparing MYL-1501D, US reference insulin glargine (US IG), and European reference insulin glargine (EU IG). Materials And Methods: The double-blind, randomized, three-way crossover...
3.
Blevins T, Barve A, Raiter Y, Aubonnet P, Athalye S, Sun B, et al.
Diabetes Obes Metab
. 2019 Nov;
22(3):365-372.
PMID: 31691472
Aims: To assess the efficacy, insulin dose, safety and immunogenicity when people with type 1 diabetes mellitus switched between MYL-1501D and reference insulin glargine (Lantus®; Sanofi-Aventis US LLC, Bridgewater, New...
4.
Blevins T, Barve A, Sun B, Raiter Y, Aubonnet P, Muniz R, et al.
Diabetes Obes Metab
. 2018 Aug;
21(1):129-135.
PMID: 30112792
Aims: To assess the non-inferiority of MYL-1501D, a proposed biosimilar or follow-on biological agent to marketed insulin glargine, to reference insulin glargine (Lantus®; Sanofi-Aventis US LLC, Bridgewater, New Jersey) based...
5.
Foucher C, Aubonnet P, Reichert P, Berli M, Schaeffer A, Calvo Vargas C, et al.
Cardiovasc Ther
. 2015 Aug;
33(6):329-37.
PMID: 26227087
Aims: Guidelines propose additional therapy to statin to treat elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDLC) in dyslipidemic patients. We evaluated the effects of new fixed-dose combinations (FDC)...
6.
Massin P, Peto T, Ansquer J, Aubonnet P, MacuFEN Study Investigators F
Ophthalmic Epidemiol
. 2014 Aug;
21(5):307-17.
PMID: 25133794
Purpose: Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing...
7.
Winsemius A, Ansquer J, Olbrich M, van Amsterdam P, Aubonnet P, Beckmann K, et al.
J Clin Pharmacol
. 2014 Apr;
54(9):1038-47.
PMID: 24691799
Simvastatin and fenofibrate are frequently co-prescribed at staggered intervals for the treatment of dyslipidemia. Since a drug-drug interaction has been reported when the two drugs are given simultaneously, it is...
8.
Morgan C, Owens D, Aubonnet P, Carr E, Jenkins-Jones S, Poole C, et al.
BMJ Open
. 2013 Dec;
3(12):e004025.
PMID: 24302508
Objectives: To compare the progression of diabetic retinopathy (DR) in people with type 2 diabetes treated with fibrates with that of non-exposed controls. Design: Retrospective, matched cohort study. Setting: UK...